Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial

Background ITALUNG is contributing to the European evaluation of low-dose CT (LDCT) screening for lung cancer (LC). Methods Eligible subjects aged 55–69 years, smokers or ex-smokers (at least 20 pack-years in the last 10 years), were randomised to receive an annual invitation for LDCT screening for 4 years (active group) or to usual care (control group). All participants were followed up for vital status and cause of death (at the end of 2014) and LC incidence (at the end of 2013). Pathological and clinical information was collected from the Tuscan Cancer Registry data. Results 1613 subjects were randomly assigned to the active group and 1593 to the control group. At the end of the follow-up period 67 LC cases were diagnosed in the active group and 71 in the control group (rate ratio (RR)=0.93; 95% CI 0.67 to 1.30). A greater proportion of stage I LC was observed in the active group (36% vs 11%, p<0.001). Non-significant reductions of 17% (RR=0.83; 95% CI 0.67 to 1.03) for overall mortality and 30% (RR=0.70; 95% CI 0.47 to 1.03) for LC-specific mortality were estimated. Conclusions Despite the lack of statistical significance, the ITALUNG trial outcomes suggest that LDCT screening could reduce LC and overall mortality. Moreover, the comparison of the number of LC cases diagnosed in the two groups does not show overdiagnosis after an adequate follow-up period. A pooled analysis of all European screening trials is advocated to assess the benefit-to-harm ratio of LDCT screening and its implementation in public health settings. Trial registration number Results, NCT02777996.

[1]  M. Mascalchi,et al.  Does UKLS strategy increase the yield of screen-detected lung cancers? A comparison with ITALUNG , 2016, Thorax.

[2]  M. Stafoggia,et al.  [Italian cancer figures, report 2011: Survival of cancer patients in Italy]. , 2011, Epidemiologia e prevenzione.

[3]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[4]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[5]  C. Cirilli,et al.  Key factors influencing lung cancer survival in northern Italy. , 2013, Cancer epidemiology.

[6]  J. Habbema,et al.  Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON) , 2007, International journal of cancer.

[7]  V. Moyer.  Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2014, Annals of Internal Medicine.

[8]  P. Pinsky,et al.  Lung Cancer Mortality in the Lung Screening Study Feasibility Trial , 2018, JNCI cancer spectrum.

[9]  E. Paci,et al.  Predictors of smoking cessation within a lung cancer CT screening trial , 2011 .

[10]  A. Dirksen,et al.  The Danish Randomized Lung Cancer CT Screening Trial—Overall Design and Results of the Prevalence Round , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  P. V. van Ooijen,et al.  Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval , 2016, Thorax.

[12]  Eugenio Paci,et al.  Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. , 2009, Lung cancer.

[13]  Stephanie J. C. Taylor,et al.  Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations. , 2016, Health technology assessment.

[14]  R. V. van Klaveren,et al.  The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. , 2006, Journal of Thoracic Oncology.

[15]  S. Gallus,et al.  Predicting the future prevalence of cigarette smoking in Italy over the next three decades. , 2012, European journal of public health.

[16]  C. la Vecchia,et al.  Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[17]  E. Kuipers,et al.  European Code against Cancer, 4th Edition: Cancer screening. , 2015, Cancer epidemiology.

[18]  John K Field,et al.  The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. , 2016, Health technology assessment.

[19]  H. Kauczor,et al.  Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up After Randomization , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  M. L. R. D. Christenson,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[21]  E. Paci,et al.  Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. , 2012, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[22]  A. Dirksen,et al.  CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT , 2012, Thorax.

[23]  Ugo Pastorino,et al.  Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[24]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[25]  H. D. de Koning,et al.  European randomized lung cancer screening trials: Post NLST , 2013, Journal of surgical oncology.

[26]  N J Wald,et al.  UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening , 2015, Thorax.

[27]  Federico Cappuzzo,et al.  Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. , 2008, Lung cancer.

[28]  S. Duffy,et al.  CT screening for lung cancer: Is the evidence strong enough? , 2016, Lung cancer.

[29]  M. Price,et al.  The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. , 2016, Health technology assessment.

[30]  M. Scorsetti,et al.  Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. , 2015, American journal of respiratory and critical care medicine.

[31]  M. Roizen.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[32]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[33]  M. Mascalchi,et al.  Four-Year Results of Low-Dose CT Screening and Nodule Management in the ITALUNG Trial , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.